Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: anticancer therapeutics - Rexahn

Drug Profile

Research programme: anticancer therapeutics - Rexahn

Alternative Names: RX-0183; RX-1792; RX-1834; RX-5315; RX-8243

Latest Information Update: 04 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Rexahn Pharmaceuticals
  • Class Isoquinolines; Piperazines; Quinazolines; Quinoxalines; Small molecules
  • Mechanism of Action Aurora kinase A inhibitors; Microtubule protein inhibitors; Proto oncogene protein c-akt inhibitors; Proto oncogene proteins c fos inhibitors; RNA helicase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Solid tumours

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Solid-tumours in USA
  • 14 Jul 2015 Rexahn has patent protection for CPMA drug delivery technology in Japan
  • 17 Jan 2012 This programme is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top